Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir

Clinical Therapeutics

Volumn 23, Issue 10, 2001, Pages 1603-1614

  Hetherington, Seth ^a   McGuirk, Sue ^b   Powell, Gwendolyn ^a   Cutrell, Amy ^a   Naderer, Odin ^a   Spreen, Bill ^a   Lafon, Steve ^a   Pearce, Gill ^b   Steel, Helen ^b  

^a GLAXOSMITHKLINE   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Abacavir; Adverse effects; Drug hypersensitivity; Nucleoside reverse transcriptase inhibitor

Indexed keywords

ABACAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

CLINICAL EXAMINATION; CLINICAL TRIAL; COUGHING; DYSPNEA; FATIGUE; FEVER; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERSENSITIVITY REACTION; HYPOTENSION; INCIDENCE; MALAISE; MEDICAL RECORD; MORTALITY; PHARYNGITIS; RASH; RESPIRATORY TRACT DISEASE; RETROSPECTIVE STUDY; REVIEW; SYMPTOM;

EID: 0035163638     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(01)80132-6     Document Type: Article

References (37)

1. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial
2. A randomized, double-blind study of triple nucleoside therapy of abacavir, lamivudine, and zidovudine versus lamivudine and zidovudine in previously treated human immunodeficiency virus type 1-infected children
3. Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults
4. A close-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment-naive subjects
5. Risk factor analysis for hypersensitivity reactions to abacavir
6. Mechanisms of drug reactions: The metabolic track
7. Allergic reactions to drugs and biologic agents
8. Role of drug disposition in drug hypersensitivity: A chemical, molecular, and clinical perspective
9. The immunologic and metabolic basis of drug hypersensitivities
10. Dermatologic complications associated with administration of 2′,3′-dideoxycytidine in patients with human immunodeficiency virus infection
11. Allergy and desensitization to zidovudine in patients with acquired immunodeficiency syndrome (AIDS)
12. Hypersensitivity to zidovudine: Report of a case of anaphylaxis and review of the literature
13. Hypersensitivity syndrome associated with zalcitabine therapy
14. DRESS (drug rash with eosinophilia and systemic symptoms) syndrome associated with nevirapine therapy
15. Nevirapine-associated Stevens-Johnson syndrome
16. Acute hypersensitivity with delavirdine
17. Hypersensitivity syndrome associated with efavirenz therapy
18. Hypersensitivity reactions during antiretroviral regimens with protease inhibitors
19. Severe adverse cutaneous reactions to drugs
20. Pathogenesis of hypersensitivity reactions to drugs in patients with HIV infection: Allergic or toxic?
21. Clinical experience with non-nucleoside reverse transcriptase inhibitors
22. Nevirapine and rashes
23. A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV-infected patients
24. Fever, erythroderma, abdominal pain, and renal failure following initiation of indinavir therapy
25. Severe allergic reaction after repeated exposure to indinavir
26. Acute respiratory failure associated with the human immunodeficiency virus (HIV) protease inhibitor indinavir in an HIV-infected patient
27. Executive summary of disease management of drug hypersensitivity: A practice parameter
28. New concepts in immunology relevant to idiosyncratic drug reactions: The "danger hypothesis" and innate immune system
29. Abacavir induced hypersensitivity in HIV infected individuals is associated with an increased frequency of Th0 T cells
30. Hypersensitivity syndrome to abacavir - Confirmation by skin testing
31. Abacavir rechallenge has to be avoided in case of hypersensitivity reaction
32. Risk factors for drug allergy
33. Idiosyncratic drug reactions: The reactive metabolite syndromes
34. Efficacy of a short-term prednisone regimen in nevirapine-associated rash prevention: A double-blind placebo-controlled clinical trial. Results of the GESIDA 09/99 study
35. Examination of trials to prevent nevirapine (NVP)-associated rash
36. Interruptions in abacavir dosing are not associated with increased risk of hypersensitivity in the HEART (NZTA4006) study
37. Severe anaphylactic shock after rechallenge with abacavir without preceding hypersensitivity